Royalty Pharma (RPRX) Other Accumulated Expenses (2020 - 2026)

Royalty Pharma (RPRX) has 7 years of Other Accumulated Expenses data on file, last reported at $17.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 6.02% year-over-year to $17.5 million; the trailing twelve-month figure through Mar 2026 stood at $17.5 million (down 6.02% YoY), and the FY2025 full-year result was $53.2 million, down 22.5% from the prior year.
• Other Accumulated Expenses retreated to $17.5 million in Q1 2026, from $53.2 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $97.5 million in Q2 2024 to a low of $3.1 million in Q2 2025.
• A 5-year average of $29.6 million and a median of $17.5 million in 2026 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses soared 503.08% in 2024 and slumped 96.85% in 2025, its largest moves.
• Tracing RPRX's Other Accumulated Expenses over 5 years: stood at $12.4 million in 2022, then slipped by 8.27% to $11.4 million in 2023, then soared by 503.08% to $68.6 million in 2024, then declined by 22.5% to $53.2 million in 2025, then plunged by 67.12% to $17.5 million in 2026.
• Business Quant data shows RPRX's Other Accumulated Expenses at $17.5 million in Q1 2026, $53.2 million in Q4 2025, and $3.1 million in Q3 2025.